ArticleInsights into imaging2025
Contrast-enhanced mammography for breast cancer detection and diagnosis with high concentration iodinated contrast medium.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Sustainability of contrast-enhanced breast imaging: a review of current evidence.Insights into imaging · 2026Review
- Calibrated Transformer Fusion for Dual-View Low-Energy CESM Classification.Journal of imaging · 2026Article
- Contrast-Enhanced Mammography and Deep Learning-Derived Malignancy Scoring in Breast Cancer Molecular Subtype Assessment.Medicina (Kaunas, Lithuania) · 2026Article
- Preoperative Breast MRI and Histopathology in Breast Cancer: Concordance, Challenges and Emerging Role of CEM and mpMRI.Diagnostics (Basel, Switzerland) · 2025Review
- Why study design matters: evaluating bias and generalizability in contrast-enhanced mammography research.Insights into imaging · 2025Article
- Why clinical context and sustainability matters: the role of high-concentration contrast in CEM.Insights into imaging · 2025Article
- From Innovation to Application: Can Emerging Imaging Techniques Transform Breast Cancer Diagnosis?Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe assessed the diagnostic performance of contrast-enhanced mammography (CEM) using a high-concentration iodinated contrast medium (HCCM, 400 mgI/mL) to determine whether the reduced iodine dose and increased iodine delivery rate (IDR) achieved might offer a more sustainable alternative to CEM performed with lower iodine concentrations.
methodsThis two-center retrospective study included 205 patients who underwent CEM between March 2021 and February 2022. Patients were injected with HCCM at 1.0 mL/kg bodyweight at an IDR of 1.2 gL/s. Standard cranio-caudal and mediolateral-oblique views were acquired. Images were reviewed independently by two experienced radiologists who were blinded to patient clinical and imaging information. Diagnostic performance, including sensitivity, specificity, and accuracy, was assessed based on histological or long-term imaging follow-up as the reference standard.
resultsAmong the 205 patients, 149 (72.7%) had malignant lesions, and 56 (27.3%) had benign findings. The sensitivity and specificity of CEM were 96-97% and 84-87.5%, respectively, with an overall accuracy of 93-95%. The IDR achieved with HCCM resulted in excellent contrast enhancement, particularly in patients with aggressive malignancies. ROC analysis confirmed the good diagnostic performance, with AUC values of 0.90-0.92. Compared to conventional mammography and ultrasound, CEM demonstrated significantly higher diagnostic accuracy, especially in patients with dense breast tissue.
conclusionsCEM with HCCM provides excellent diagnostic performance, achieving high sensitivity and specificity while allowing for a reduced iodine dose and increased IDR. This approach may offer a more sustainable alternative to conventional contrast media without compromising diagnostic accuracy, particularly for the detection and characterization of aggressive breast lesions. CRITICAL RELEVANCE STATEMENT: This study demonstrates that reducing the volume of injected contrast media while increasing iodine concentration maintains the diagnostic benefits of CEM, further supporting its potential to improve early cancer detection, thereby advancing clinical radiology practices and optimizing screening strategies for women with dense breasts. KEY POINTS: Currently, CEM protocols utilize a variety of iodine concentrations and flow rates. CEM with high-concentration contrast (400 mgI/mL) achieved 96% sensitivity and 87.5% specificity. High-concentration contrast in CEM improves early detection of aggressive breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.